Sarah E Cusick1, Robert O Opoka2, Andrew S Ssemata2, Michael K Georgieff1, Chandy C John1,3. 1. Department of Pediatrics, University of Minnesota School of Medicine, Minneapolis, MN, USA. 2. Department of Paediatrics and Child Health, Makerere University College of Health Sciences, Kampala, Uganda. 3. Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA.
Abstract
BACKGROUND: WHO guidelines recommend concurrent iron and antimalarial treatment in children with malaria and iron deficiency, but iron may not be well absorbed or utilized during a malaria episode. OBJECTIVES: We aimed to determine whether starting iron 28 d after antimalarial treatment in children with severe malaria and iron deficiency would improve iron status and lower malaria risk. METHODS: We conducted a randomized clinical trial on the effect of immediate compared with delayed iron treatment in Ugandan children 18 mo-5 y of age with 2 forms of severe malaria: cerebral malaria (CM; n = 79) or severe malarial anemia (SMA; n = 77). Asymptomatic community children (CC; n = 83) were enrolled as a comparison group. Children with iron deficiency, defined as zinc protoporphyrin (ZPP) ≥ 80 µmol/mol heme, were randomly assigned to receive a 3-mo course of daily oral ferrous sulfate (2 mg · kg-1 · d-1) either concurrently with antimalarial treatment (immediate arm) or 28 d after receiving antimalarial treatment (delayed arm). Children were followed for 12 mo. RESULTS: All children with CM or SMA, and 35 (42.2%) CC, were iron-deficient and were randomly assigned to immediate or delayed iron treatment. Immediate compared with delayed iron had no effect in any of the 3 study groups on the primary study outcomes (hemoglobin concentration and prevalence of ZPP ≥ 80 µmol/mol heme at 6 mo, malaria incidence over 12 mo). However, after 12 mo, children with SMA in the delayed compared with the immediate arm had a lower prevalence of iron deficiency defined by ZPP (29.4% compared with 65.6%, P = 0.006), a lower mean concentration of soluble transferrin receptor (6.1 compared with 7.8 mg/L, P = 0.03), and showed a trend toward fewer episodes of severe malaria (incidence rate ratio: 0.39; 95% CI: 0.14, 1.12). CONCLUSIONS: In children with SMA, delayed iron treatment did not increase hemoglobin concentration, but did improve long-term iron status over 12 mo without affecting malaria incidence.This trial was registered at clinicaltrials.gov as NCT01093989.
BACKGROUND: WHO guidelines recommend concurrent iron and antimalarial treatment in children with malaria and iron deficiency, but iron may not be well absorbed or utilized during a malaria episode. OBJECTIVES: We aimed to determine whether starting iron 28 d after antimalarial treatment in children with severe malaria and iron deficiency would improve iron status and lower malaria risk. METHODS: We conducted a randomized clinical trial on the effect of immediate compared with delayed iron treatment in Ugandan children 18 mo-5 y of age with 2 forms of severe malaria: cerebral malaria (CM; n = 79) or severe malarial anemia (SMA; n = 77). Asymptomatic community children (CC; n = 83) were enrolled as a comparison group. Children with iron deficiency, defined as zinc protoporphyrin (ZPP) ≥ 80 µmol/mol heme, were randomly assigned to receive a 3-mo course of daily oral ferrous sulfate (2 mg · kg-1 · d-1) either concurrently with antimalarial treatment (immediate arm) or 28 d after receiving antimalarial treatment (delayed arm). Children were followed for 12 mo. RESULTS: All children with CM or SMA, and 35 (42.2%) CC, were iron-deficient and were randomly assigned to immediate or delayed iron treatment. Immediate compared with delayed iron had no effect in any of the 3 study groups on the primary study outcomes (hemoglobin concentration and prevalence of ZPP ≥ 80 µmol/mol heme at 6 mo, malaria incidence over 12 mo). However, after 12 mo, children with SMA in the delayed compared with the immediate arm had a lower prevalence of iron deficiency defined by ZPP (29.4% compared with 65.6%, P = 0.006), a lower mean concentration of soluble transferrin receptor (6.1 compared with 7.8 mg/L, P = 0.03), and showed a trend toward fewer episodes of severe malaria (incidence rate ratio: 0.39; 95% CI: 0.14, 1.12). CONCLUSIONS: In children with SMA, delayed iron treatment did not increase hemoglobin concentration, but did improve long-term iron status over 12 mo without affecting malaria incidence.This trial was registered at clinicaltrials.gov as NCT01093989.
Authors: Meghna R Desai; Joanne V Mei; Simon K Kariuki; Kathleen A Wannemuehler; Penelope A Phillips-Howard; Bernard L Nahlen; Piet A Kager; John M Vulule; Feiko O ter Kuile Journal: J Infect Dis Date: 2003-02-07 Impact factor: 5.226
Authors: Caitlin T Howard; Uri S McKakpo; Isabella A Quakyi; Kwabena M Bosompem; Ebenezer A Addison; Kai Sun; David Sullivan; Richard D Semba Journal: Am J Trop Med Hyg Date: 2007-10 Impact factor: 2.345
Authors: Sarah E Cusick; Robert O Opoka; Andrew S Ssemata; Michael K Georgieff; Chandy C John Journal: Am J Clin Nutr Date: 2016-02-03 Impact factor: 7.045
Authors: Jacobien Veenemans; Paul Milligan; Andrew M Prentice; Laura R A Schouten; Nienke Inja; Aafke C van der Heijden; Linsey C C de Boer; Esther J S Jansen; Anna E Koopmans; Wendy T M Enthoven; Rob J Kraaijenhagen; Ayse Y Demir; Donald R A Uges; Erasto V Mbugi; Huub F J Savelkoul; Hans Verhoef Journal: PLoS Med Date: 2011-11-22 Impact factor: 11.069
Authors: Andrew M Prentice; Conor P Doherty; Steven A Abrams; Sharon E Cox; Sarah H Atkinson; Hans Verhoef; Andrew E Armitage; Hal Drakesmith Journal: Blood Date: 2012-01-06 Impact factor: 22.113
Authors: Paul Bangirana; Chandy C John; Richard Idro; Robert O Opoka; Justus Byarugaba; Anne M Jurek; Michael J Boivin Journal: PLoS One Date: 2009-11-19 Impact factor: 3.240
Authors: Andrea L Conroy; Robert O Opoka; Paul Bangirana; Ruth Namazzi; Allen E Okullo; Michael K Georgieff; Sarah Cusick; Richard Idro; John M Ssenkusu; Chandy C John Journal: BMC Med Date: 2021-07-28 Impact factor: 8.775